We are live on ! Find out more

Silo Pharma

SILO

Market cap $3.09M

1.76 USD

-0.18

9.28%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

1.79

+0.03

1.7%

1 day

-9.28%

5 days

-19.27%

1 month

-42.67%

3 months

-71.84%

6 months

-65.83%

Year to date

-65.01%

1 year

-83.85%

5 years

-97.7%

10 years

-97.7%

About: SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Employees: 3

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 16.7%

Neutral 83.3%

Negative 0%

Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum

SARASOTA, FLA., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), ”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, today announced that company representatives will participate in the upcoming IPAC-RS 2026 Nasal Innovation Forum to be held September 16-17, 2026, in Jersey City, New Jersey.

Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform

Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership

Silo Pharma Incs (NASDAQ:SILO) announced on Tuesday that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices Inc.'s (NASDAQ:AMD) AI Developer Program, providing access to cloud computing credits, AI development tools, training resources, and a global developer network aimed at accelerating the platform's growth.

Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash

Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives

NVIDIA Corp. (NASDAQ:NVDA) expanded its presence in life sciences AI through separate initiatives with Certara Inc. (NASDAQ:CERT) and Silo Pharma Inc. (NASDAQ:SILO).

Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives

Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program

NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing

Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program

Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request

Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system

Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request

See News Rankings

Price charts implemented using Lightweight Charts™